Barclays’s Insys Therapeutics, Inc. INSY Stock Holding History

Barclays’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,300	Closed	-$6K	–	7535
2019 Q1	$6K	Sell	1,300 -3,500	-73%	-$16.6K	﹤0.01%	6694
2018 Q4	$17K	Sell	4,800 -800	-14%	-$5.56K	﹤0.01%	5986
2018 Q3	$56K	Buy	5,600 +2,000	+56%	+$16K	﹤0.01%	6015
2018 Q2	$26K	Sell	3,600 -49,000	-93%	-$342K	﹤0.01%	6048
2018 Q1	$318K	Sell	52,600 -400	-0.8%	-$3.3K	﹤0.01%	4412
2017 Q4	$510K	Buy	53,000 +52,700	+17,567%	+$345K	﹤0.01%	3811
2017 Q3	$3K	Sell	300 -2,600	-90%	-$26.8K	﹤0.01%	6634
2017 Q2	$37K	Buy	+2,900	New	+$34.3K	﹤0.01%	5511
2017 Q1	–	Sell	-6,200	Closed	-$57K	–	7123
2016 Q4	$57K	Buy	+6,200	New	+$70K	﹤0.01%	5088

Barclays's INSY Position: Q3 2019 in Review

Barclays sold out of Insys Therapeutics, Inc. (INSY) in Q3 2019, closing a stake of 33,172 shares — an estimated $10K sold.

Barclays first reported a position in INSY in Q2 2013 and held it in 24 quarters. The position peaked at $5.19M in Q3 2015. 4 funds tracked by Wall St. Rank hold INSY as of Q3 2019.

Barclays reported no remaining Insys Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Barclays sold 33,172 Insys Therapeutics, Inc. shares in Q3 2019, an estimated $10K.
Barclays first reported a position in Insys Therapeutics, Inc. in Q2 2013 and held it in 24 quarters.
Barclays's Insys Therapeutics, Inc. position peaked at $5.19M in Q3 2015.
4 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2019.

Based on Barclays's 13F filing for Q3 2019, filed 14 Nov 2019.